FotoFinder Systems: Artificial Intelligence Revolutionizes Skin Cancer Detection
"Artificial Intelligence" (AI) is currently on everyone's lips. Experts say companies need to focus on three aspects of AI to play a leading role in the topic: latest programming insights, importance of data and AI integration into existing workflows. FotoFinder Systems already combines these key aspects today. As a pioneer, the high-tech company is a leader in integrating AI into technology for skin cancer diagnostics. With the new expert software Moleanalyzer pro, dermatologists are able to assess moles with AI. Validation results confirm an extremely high accuracy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190109005031/en/
Artificial Intelligence in skin cancer detection (Copyright tiler84, iStock)
High-tech meets specialist expertise
Moleanalyzer pro offers physicians the possibility to confirm their diagnosis with various evaluation techniques. For the first time, it is possible to combine specialist expertise with AI and additionally to receive a second opinion – per mouse click – from renowned international skin cancer experts.
AI in dermoscopy
Moleanalyzer pro works with deep learning: The human ability to learn from examples and experiences was transferred to the computer. For this purpose the “Convolutional Neural Network” (CNN) was trained with the currently largest data collection of dermoscopic images including corresponding diagnosis. Due to many years of valuable cooperation with physicians worldwide, the continuous "feeding" of the algorithm succeeds. With growing experience and its own autonomous rules, it is able to distinguish between benign and malignant lesions. The result is a score that supports the risk assessment of both melanocytic and non-melanocytic skin lesions. Shortly, this AI Score will be available for doctors also on mobile devices.
Validated, precise, self-learning
According to the representative study "Man against machine"*, the deep learning algorithm showed an impressively high sensitivity by correctly identifying 95% of malignant skin tumors. In the comparison group, the experts – 58 dermatologists from 17 nations – identified 86.6% of the lesions as malignant. The algorithm also showed a reliably high specificity by identifying 82.5% of benign nevi correctly, while the experts identified 71.3% as benign.
Artificial Intelligence meets human experience
As fascinating as AI is, it cannot replace human experience in the matter of skin cancer. In the end, the doctor decides what to do. In case of doubt, Moleanalyzer pro offers a second opinion service from internationally renowned skin cancer specialists to confirm the diagnosis.
About FotoFinder Systems
Founded in 1991 the German company is specialized in skin cancer diagnostics by means of Automated Total Body Mapping, digital dermoscopy, in hair diagnostics, psoriasis documentation and imaging in aesthetics. Subsidiaries in Italy, Spain, UK and the U.S. and a global partner network support the company’s worldwide presence. FotoFinder won the Bavarian Export Award, Red Dot Design Award and was honored as one of the most innovative companies in Lower Bavaria.
* "Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists", by H.A. Haenssle et al. Annals of Oncology. doi:10.1093/annonc/mdy166
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Proteus Digital Health® Founder to Present at World Economic Forum in Davos21.1.2019 21:54 | Tiedote
Proteus Digital Health® announced today that Andrew Thompson, its President, Chief Executive Officer and Co-Founder, will present on the progress of Proteus’ digital medicines to improve patient treatment and outcomes at the 2019 World Economic Forum Annual Meeting in Davos-Klosters, Switzerland. Mr. Thompson will present on the official programme: With leaders from financial and academic institutions to address “Theory of the Firm in a World of Digital Ecosystems,” on Tuesday, January 22 beginning at 9:45 a.m. CET in the Congress Centre, Jakobshorn; and Joining state and religious leaders in the Open Forum “Bridging Science with Society,” scheduled to begin at 9:00 a.m. CET on Friday, January 25 at the Swiss Alpine High School Auditorium. This session will be live-streamed on TopLink and the Forum website. Mr. Thompson will also present at two other events during the World Economic Forum Meeting: January 22 at 8:05 p.m., Polish House: Mr. Thompson will provide a keynote address on the
CNIM Is to Equip the French Navy with 14 New Standard Amphibious Landing Craft (EDA-S)21.1.2019 21:36 | Tiedote
CNIM - in partnership with Socarenam, Mauric and CNN MCO - has been awarded the contract to replace the French Navy's landing crafts. Fourteen new Standard Amphibious Landing Crafts (EDA-S) are to be built over a ten-year period. This contract reasserts CNIM's status as a key partner to the French Navy and a European leader in the area of amphibious operations, supplying the complementary innovative vessels: EDA-S and EDA-R (already in service in the French Navy, designed by CNIM). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005420/en/ CNIM is to equip the French Navy with 14 new Standard Amphibious Landing Craft (EDA-S) - (c) CNIM Next-generation of vessels designed by CNIM "Winning this European tender reasserts CNIM's status as experts in amphibious craft design. CNIM is to replace the French Navy's existing landing craft with fourteen new Standard Amphibious Landing Craft, also called EDA-S", notes Philippe Demi
Naspers Progresses Plans to List MultiChoice Group Limited and Unbundle Its Shares in MultiChoice Group to Naspers Shareholders21.1.2019 19:04 | Tiedote
On 17 September 2018, Naspers Limited (JSE: NPN; LSE: NPSN) announced its intention to list its video entertainment business separately on the Johannesburg Stock Exchange (JSE) as MultiChoice Group Limited (MultiChoice Group) and simultaneously unbundle its shares in this business to Naspers shareholders. It is expected that the Admission and dealings in the Shares will commence on Wednesday, 27 February 2019. In relation to the Admission, MultiChoice Group today published a pre-listing statement compliant with the requirements of the JSE. MultiChoice South Africa (MCSA), MultiChoice Africa, Showmax and Irdeto and their subsidiaries and affiliates, will, among others, be subsidiaries of MultiChoice Group. MultiChoice Group is the leading video entertainment operator on the African continent, with an extensive local and international content offering. It is one of the fastest-growing pay-TV broadcast providers globally and provides entertainment to around 14 million households across 50
MultiChoice Group Limited (MCG) Today Released Its Pre-Listing Statement in Compliance with the JSE Listings Requirements21.1.2019 18:59 | Tiedote
Naspers Limited (JSE: NPN; LSE: NPSN) : MultiChoice Group Limited (MCG) today released its pre-listing statement in compliance with the JSE Listings Requirements (www.multichoice.com) providing further details about its listing on the Johannesburg Stock Exchange (JSE). Trading in MCG shares is expected to commence on the JSE on Wednesday, 27 February 2019. As announced on 17 September 2018, MCG will include, amongst others, MultiChoice South Africa (MCSA), MultiChoice Africa, Showmax, as well as the global digital platform security provider, Irdeto and all their subsidiaries and affiliates (“the Group”). Calvo Mawela, Group Chief Executive Officer of MCG said: “We believe the listing of MultiChoice provides an excellent opportunity to invest in the leading provider of video entertainment on the African continent. MCG brings an incomparable local and international content offering to around 14-million households and is one of the fastest growing pay-TV broadcast providers globally. With
ResMed’s First Top-of-Head CPAP Mask, AirFit N30i, Now Available across U.S.21.1.2019 17:05 | Tiedote
ResMed (NYSE: RMD, ASX: RMD), today introduced AirFit N30i, its first top-of-head-connected nasal CPAP mask, across the United States, with a newly designed nasal cradle cushion that sits just under the wearer’s nose. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005035/en/ AirFit N30i nasal CPAP mask, front view (Photo: Business Wire) The top-of-head connection keeps tubing out of the wearer’s way, letting them move and sleep in any position. The nasal cradle cushion – ResMed’s first – is designed to reduce facial markings and irritation. AirFit N30i is also convenient for equipment providers and sleep labs – it fits 96 percent of PAP users with just two frame sizes and four cushion sizes. How AirFit N30i compares to the market-leading nasal top-of-head mask In side-by-side comparisons, three out of four users preferred AirFit N30i over the other nasal mask with a top-of-head connection. A majority stated they loved
Metabolon Appoints Michael Rasche as President of International Business21.1.2019 16:06 | Tiedote
Metabolon, the world leader in metabolomics, today announced that Michael Rasche joined the company as President of International Business. Michael will report to Rohan Hastie, Metabolon’s President and CEO, and become a member of the corporate executive team. He will lead all of Metabolon's international business activities with a strong focus on customer and team expansion. "We are thrilled to have Michael join the Metabolon team," said Hastie. "Michael brings a wealth of commercial and business experience across multiple areas of life sciences, from Pharma to Diagnostics and Biotech. I know he will make an immediate impact on our existing and future customers." "I am very excited to become part of the Metabolon success story," added Rasche. "I will passionately lead our team to drive accelerated business expansion across all international markets. Our Precision Metabolomics™ technology is delivering biomarker discoveries, innovative diagnostic tests, and groundbreaking data in genom
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme